Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sona NanotechSNANF +6.69%26 EV-to-EBITDA is -20.70 as of Aug. 12, 2026. GuruFocus rates SNANF with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 398 Biotechnology companies, Sona Nanotech ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sona Nanotech's enterprise value is $29.94 Mil.
Sona Nanotech's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $-1.45 Mil. Therefore, Sona Nanotech's EV-to-EBITDA for today is -20.70.
The historical rank and industry rank for Sona Nanotech's EV-to-EBITDA or its related term are showing as below:
SNANF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.73 Med: 0 Max: 0
Current: -20.7
SNANF's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs SNANF: -20.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sona Nanotech (OTCPK:SNANF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sona Nanotech's PE Ratio (TTM) for today is calculated as:
Sona Nanotech's share price for today is $0.2497.
Sona Nanotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sona Nanotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNANF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Sona Nanotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sona Nanotech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sona Nanotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sona Nanotech's EV-to-EBITDA falls into.
Sona Nanotech's current Enterprise Value is $29.94 Mil.
Sona Nanotech's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sona Nanotech (SNANF) has a EV-to-EBITDA of -20.70 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sona Nanotech. According to the industry distribution chart, Sona Nanotech ranks #999999 out of 398 companies in the Biotechnology industry.
Is Sona Nanotech's EV-to-EBITDA too high?
Sona Nanotech's current EV-to-EBITDA is -20.70. Based on the distribution chart, Sona Nanotech ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sona Nanotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Sona Nanotech's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sona Nanotech ranks #999999 out of 398 companies for EV-to-EBITDA. This places Sona Nanotech in the lower half of its industry. The industry median EV-to-EBITDA is 13.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sona Nanotech. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sona Nanotech's current EV-to-EBITDA is -20.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sona Nanotech stock overvalued right now?
Sona Nanotech (SNANF) has a current EV-to-EBITDA of -20.70. The current EV-to-EBITDA is -20.70. Sona Nanotech's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sona Nanotech (SNANF), the current EV-to-EBITDA is -20.70 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sona Nanotech Inc is involved in the nanotechnology life sciences industry. It has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles and is engaged in the research and development of its proprietary technology for use in biomedical applications and multiplex diagnostic testing platforms. The company is using its gold nano rods manufacturing technology to develop new products and methods for cancer treatment, including a Targeted Hyperthermia Therapy (THT). Additionally, it has filed patent applications in the U.S. regarding a gold nanorod conjugation concept for targeted drug delivery, combination therapies for treating cancer, and for an endoscope with an optical fibre and thermal sensor for photothermal therapy.
26GF Score
Get the complete analysis for SNANF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNANF has been successfully added to your 
